Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis
Key claim: A Phase 2 trial is evaluating whether adding bomedemstat (LSD1 inhibitor) to momelotinib improves outcomes in myelofibrosis patients with suboptimal response to momelotinib monotherapy or baseline cytopenias.
Abstract
This is an open-label, single-arm, Phase 2 interventional study designed to evaluate the safety and efficacy of Bomedemstat (IMG-7289) when added to Momelotinib in patients with Myelofibrosis (MF) who exhibit a suboptimal response to Momelotinib alone or who present with baseline cytopenias and do not achieve adequate improvement after 12 weeks of Momelotinib monotherapy.
The study consists of three phases:
- Screening Phase (up to 28 days)
- Momelotinib Monotherapy Phase - Weeks 0-12
- Combination Treatment Phase (Momelotinib + Bomedemstat) - Weeks 12-24
- Post-Treatment Follow-up Phase (30 days post last dose + long-term survival follow-up) All patients will continue on Momelotinib throughout the study unless toxicity or safety considerations necessitate modification.
Why this matters
This trial extends the LSD1-inhibitor combination strategy from iadademstat+ASTX727 in advanced/blast-phase MPN into the chronic-phase cytopenic and JAKi-suboptimal PMF niche, and is the first to pair an LSD1 inhibitor with momelotinib specifically (rather than ruxolitinib). For PMF natural history, it addresses a defined subpopulation — patients with baseline cytopenias or inadequate response to JAK inhibition — where standard JAKi monotherapy has limited efficacy. If positive, it would establish epigenetic LSD1 targeting as a viable add-on across the cytopenic MF spectrum.